|Bid||4.7700 x 1200|
|Ask||4.8400 x 800|
|Day's Range||4.7501 - 5.0500|
|52 Week Range||4.2800 - 8.2400|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate. This study's objective was to assess neurotoxicity resulting from a long residence time of a local anesthetic in proximity to the sciatic nerve in rabbits. The rabbit limbs dosed with the liposomal prolonged bupivacaine release (Probudur), at ten times more than free bupivacaine, showed no nerve damage signs. Further, nerves injected with Probudur showed mild signs of inflammation and small residues of the hydrogel in granulomas, indicating a long residence time of the hydrogel at the injection site, but no histopathological signs of nerve damage. Price Action: VRPX shares are up 5.26% at $5.1 during the market trading session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaJohnson & Johnson Becomes Third Company To Expand COVID-19 Vaccine Study To AdolescentsMolecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
BERWYN, PA / ACCESSWIRE / April 5, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the results of a sciatic nerve preclinical study in rabbits designed to evaluate nerve damage from locally injected Probudur™, Virpax's liposomal bupivacaine product candidate.
BERWYN, PA / ACCESSWIRE / March 22, 2021 / Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that preclinical studies of Probudur™, a proprietary patented injectable, long-acting "local anesthetic" Liposomal (Hydro) Gel Technology for postoperative pain management, have been initiated under an agreement with Charles River Laboratories.